Using metabolic 'pollution' to target improved anticancer treatments

March 26, 2012 By Greg Hand
UC researcher announces progress toward new chemotherapy agents
Edward J. Merino

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

Merino will discuss his efforts toward designing these new Tuesday, March 27, at The Chemistry of Life: Spring National Meeting and Exposition of the American Chemical Society in San Diego.

At that meeting, Merino will show a new anticancer agent that targets cancerous by zeroing-in on the “pollutants” produced by the characteristic metabolism within tumors. This agent, which Merino calls a “ROS-caged agent,” is activated by oxidative stress, a signature of cancerous activity.

“Cancerous cells use energy differently from other cells,” Merino said. “Like an automobile engine with the gas pedal pushed to the floor, they give off a unique sort of pollution because they are not as efficient in using energy. Cancer cells don’t use metabolism all the way through. We have found key enzymes that contribute to this characteristic signature.”

This signature results from the build-up of reactive oxygen species, known as ROS. This environment creates a chemical target that Merino and his team can target with chemical systems. Merino describes his findings as a preliminary description of the factors that can make drug delivery much more selective.

“We are looking for chemicals that operate like heat-seeking missiles that attack only cancerous cells,” Merino said. “If we are successful, we can create drugs with far fewer .”

The side effects associated with chemotherapy – hair loss and weight loss – are generated from the mechanism used to target today’s family of drugs. Because cancerous cells reproduce rapidly, chemotherapy targets rapidly reproducing cells. The problem, Merino said, is that cells in the stomach lining and cells in our hair follicles also reproduce rapidly – so conventional kills those cells, too.

A better understanding of cancer metabolism is an essential part of the work, but so is the basic involved in creating targeted compounds.

“We are continually making new compounds,” Merino said, “but very few of them give any indication of working. Out of hundreds of candidates, we have one moving into a mouse model, and another that looks promising.”

Merino's work is supported by the University Research Council.

Explore further: Match your treatment to your cancer

Related Stories

Match your treatment to your cancer

June 30, 2011
(Medical Xpress) -- New research has uncovered why certain cancers don’t respond to conventional chemotherapy, highlighting the need to match treatments to cancers better.

Scientists identify natural defence cells that impede chemotherapy treatment

April 27, 2011
As part of the body’s front-line defences against infection, white blood cells called macrophages often infiltrate tumours in great numbers. However, according to new research published in the scientific journal Cancer ...

Drug makes leukemia more vulnerable to chemo

March 20, 2012
(Medical Xpress) -- Doctors at Washington University School of Medicine in St. Louis have shown that a new drug makes chemotherapy more effective in treating acute myeloid leukemia, a cancer of the white blood cells. Instead ...

'Detox protein' is collaborator in pancreatic and lung cancer development

July 6, 2011
(Medical Xpress) -- UK scientists have revealed that a ‘detox’ protein which mops up harmful 'reactive oxygen' in cells could also trigger pancreatic and lung cancer development, according to a study published in ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.